Articles

Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)

Department of Oncology/Hematology, Kantonsspital St. Gallen, Switzerland
Department of Oncology/Hematology, Kantonsspital St. Gallen, Switzerland
Department of Oncology/Hematology, Kantonsspital St. Gallen, Switzerland
Slotervaart Hospital/The Netherlands Cancer Institute, Amsterdam, the Netherlands
Department of Oncology/Hematology, Kantonsspital St. Gallen, Switzerland
Department of Oncology/Hematology, Kantonsspital St. Gallen, Switzerland
SAKK Coordinating Center, Bern, Switzerland
SAKK Coordinating Center, Bern, Switzerland
SAKK Coordinating Center, Bern, Switzerland
University Hospital CHUV, Lausanne, Switzerland
University of Leiden, the Netherlands
San Giovanni hospital, Bellinzona, Switzerland
Slotervaart Hospital/The Netherlands Cancer Institute, Amsterdam, the Netherlands
Department of Medical Oncology, Inselspital, University Hospital and University of Bern, Switzerland
Hematology & Medical Oncology, Kantonsspital Graubuenden, Chur, Switzerland
Department of Oncology/Hematology, Kantonsspital St. Gallen, Switzerland
Hematology & Medical Oncology, Kantonsspital Graubuenden, Chur, Switzerland
Vol. 101 No. 3 (2016): March, 2016 https://doi.org/10.3324/haematol.2015.135780